A leading group of UK cancer experts has welcomed the announcement by Cancer Research UK that brain tumours will be a focus of their new strategy for the next five years.
The British Neuro-Oncology Society (
BNOS) says this new drive for a vitally-needed boost in funds for research could dramatically change the landscape for patients with brain cancer and their families.
Brain tumours are the biggest cancer killer of people under 40 years of age but historically the disease has only attracted around 2% of funding for research into faster diagnosis and new treatments.
“We cannot be more delighted that CRUK have announced that brain and spinal tumours will be one of the four big ‘hard to treat’ cancers to be the focus of increased research and funding. This development builds upon the successful strategy of a number of patient and family-based, as well as academic charity research initiatives which have been active over the past couple of decades.
“These groups have acted together to raise funds, through community action and through political lobbying to bring about a change in scientific attitude to the challenge of brain tumours across the ages. BNOS has been a sustained partner in this action providing the necessary scientific and clinical knowledge to inform these debates and providing a meeting point for scientific and clinical discussion of new ideas and treatments. BNOS is a major part of the European network of clinicians and scientists who meet regularly to tackle the challenge of brain tumours.”
He added: “CRUK's announcement is most welcome as they are the biggest funder of cancer research in Europe and so can bring substantial resources and cancer expertise to bear upon this subject.”
Brain tumours arise as a product of brain growth during childhood and adolescence and a product of brain degeneration during adulthood to old age. Survival and disability rates vary across the ages, in childhood survival rates are generally higher although some tumours in this age group remain incurable. In adulthood the commonest and most malignant brain tumour, glioblastoma, grade 4 astrocytoma remains resistant to treatment and although drug developments have offered some improvement recently we are still looking for a new treatment which will change the outlook for this disease.
In all ages there are tumours which are curable with surgery and radiotherapy with or without the additional effect of chemotherapy of biological therapy. The challenge is to use the experience of the successful treatments to influence understanding for the tumours which present the greater challenge.
— Ends —
Our academics can now be interviewed for broadcast via our new Globelynx fixed camera facility at the University. For further information please contact a member of the Communications team on +44 (0)115 951 5798, email mediahub@nottingham.ac.uk or see the Globelynx website for how to register for this service.
For up to the minute media alerts follow us on Twitter
Notes to editors: The University of Nottinghamhas 43,000 students and is ‘the nearest Britain has to a truly global university, with campuses in China and Malaysia modelled on a headquarters that is among the most attractive in Britain’ (Times Good University Guide 2014). It is also the most popular university among graduate employers, the world’s greenest university, and winner of the Times Higher Education Award for ‘Outstanding Contribution to Sustainable Development’. It is ranked in the World's Top 75 universities by the QS World University Rankings.
Impact: The Nottingham Campaign, its biggest-ever fundraising campaign, is delivering the University’s vision to change lives, tackle global issues and shape the future. More news…